Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
Abstract
No Abstract Available
Keywords
Intermediate, high-risk MDS; IPSS; lenalidomide; hematological response; dose-modified.
Mediterr J Hematol Infect Dis ISSN 2035-3006